Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Shares of Agios Pharmaceuticals, Inc. (AGIO) slumped 49% in the pre-market session on Wednesday after the company reported ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

The FDA will decide on a new sickle-cell drug, causing excitement and concern among physicians and patients. The time has come for the U.S. Food and Drug Administration (FDA) to decide on a new sickle ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...

PRNewswire/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik ...

Shares of Agios Pharmaceuticals sank after the company said a phase three trial of its mitapivat drug to treat Sickle Cell Disease missed some of its endpoints. The stock fell 34% to $30 after closing ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. In the years since the approval of Imbruvica for ...

Please provide your email address to receive an email when new articles are posted on . ASH issued sickle cell disease research priorities that address seven key focus areas. Topics include end-organ ...

Sickle cell awareness month, observed annually in September, is a time to raise awareness about sickle cell disease, a genetic blood disorder that affects millions of people worldwide. The Pfizer drug ...

The NDDC launches a sickle cell awareness campaign in Delta, providing medical support, drugs, and education to patients and ...